Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
'Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026' Report Highlights:
'Cancer Immunotherapy Has Emerged As Next Growth Frontier With US$ 200 Billion In Market Opportunity For Multiple Stake Holders Involved In The Research & Development Of Anti Cancer Therapies'
The immunotherapy defends the normal cells by activating the body’s immune system against the cancerous cells. The immunotherapy attractively summons the manipulated body’s own natural immune cells and causes the eviction of the cancer cells. The immunotherapy techniques such as T-cell therapy, Immune checkpoint inhibitors, Cancer vaccines, Monoclonal Antibodies and many more have offered the cancer patients with no or less hope and with substantial benefit of meaningful improvements. The growth of the respective market is attributed to the advantage that it provides of being a potential one-time treatment with long and durable response.
Different cancer immunotherapies have been developed and successfully marketed across the globe for various malignancies. They may differ in modality but all of them have some common features due to which they are in high demand among cancer patients. Development of results is apparently rapid than other cancer treatment leading to quick alleviation of clinical symptoms. As a result, more cancer patients want them to improve their medical condition in shorter time.
Improved anti-cancer efficacy is another major benefit of cancer immunotherapies which is not offered by other modalities. Fewer side effects are observed during cancer immunotherapy treatment resulting in higher tolerability and improved quality of life. Relapse prevention and increased progression free survival are also improved resulting in increased demand for cancer immunotherapies. Investigators are trying to decipher more underlying principles of cancer immunotherapies in order to offer better medical care to patients.
The aim with which the cancer immunotherapy approach came into existence was to escalate the process of cancer treatment which largely went unnoticed during usage of traditional technologies. Advanced manipulations in all the therapies of cancer immunotherapy have placed the approach above all the other available therapies for cure of cancer. The ease and the technological performance of the therapies results in long term survival of the cancer patients and a more comfortable after treatment life due to the absence of unwanted chemicals in the body and thus leading to less severe side effects. The approach has enhanced the already existing cancer treatment techniques and has marked itself as an important discovery in the field of oncology.
The strategies that are employed by the immunotherapy approach are playing a very important part in the overall medication for the cancer and that has led to the successful and rapid expansion of the overall immunotherapy market in a very short period of time. The cancer immunotherapy market is driven by the fact that the methodologies working under it have a strong clinical pipeline among which monoclonal antibodies constitutes the most widely accepted immunotherapeutic approach at the global level. The impressive rate at which the market is growing is representing a state of progress that the approach will follow in the near future.
'Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026' Report Highlights:
- Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion
- Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials
- Commercially Available Cancer Immunotherapies: > 120
- Cancer Vaccines Market Opportunity: > US$ 20 Billion
- Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion
- Marketed Cancer Monoclonal Antibodies': > 70 mAbs
- Sales, Market Opportunity, Dosage & Price Data: 300 Graphs/Charts
- Clinical Trials Insight By Phase, Company, Patient Segment, Drug Class
'Cancer Immunotherapy Has Emerged As Next Growth Frontier With US$ 200 Billion In Market Opportunity For Multiple Stake Holders Involved In The Research & Development Of Anti Cancer Therapies'
The immunotherapy defends the normal cells by activating the body’s immune system against the cancerous cells. The immunotherapy attractively summons the manipulated body’s own natural immune cells and causes the eviction of the cancer cells. The immunotherapy techniques such as T-cell therapy, Immune checkpoint inhibitors, Cancer vaccines, Monoclonal Antibodies and many more have offered the cancer patients with no or less hope and with substantial benefit of meaningful improvements. The growth of the respective market is attributed to the advantage that it provides of being a potential one-time treatment with long and durable response.
Different cancer immunotherapies have been developed and successfully marketed across the globe for various malignancies. They may differ in modality but all of them have some common features due to which they are in high demand among cancer patients. Development of results is apparently rapid than other cancer treatment leading to quick alleviation of clinical symptoms. As a result, more cancer patients want them to improve their medical condition in shorter time.
Improved anti-cancer efficacy is another major benefit of cancer immunotherapies which is not offered by other modalities. Fewer side effects are observed during cancer immunotherapy treatment resulting in higher tolerability and improved quality of life. Relapse prevention and increased progression free survival are also improved resulting in increased demand for cancer immunotherapies. Investigators are trying to decipher more underlying principles of cancer immunotherapies in order to offer better medical care to patients.
The aim with which the cancer immunotherapy approach came into existence was to escalate the process of cancer treatment which largely went unnoticed during usage of traditional technologies. Advanced manipulations in all the therapies of cancer immunotherapy have placed the approach above all the other available therapies for cure of cancer. The ease and the technological performance of the therapies results in long term survival of the cancer patients and a more comfortable after treatment life due to the absence of unwanted chemicals in the body and thus leading to less severe side effects. The approach has enhanced the already existing cancer treatment techniques and has marked itself as an important discovery in the field of oncology.
The strategies that are employed by the immunotherapy approach are playing a very important part in the overall medication for the cancer and that has led to the successful and rapid expansion of the overall immunotherapy market in a very short period of time. The cancer immunotherapy market is driven by the fact that the methodologies working under it have a strong clinical pipeline among which monoclonal antibodies constitutes the most widely accepted immunotherapeutic approach at the global level. The impressive rate at which the market is growing is representing a state of progress that the approach will follow in the near future.
1. IMMUNOTHERAPY FOR CANCER
1.1 Introduction to Cancer Immunotherapy
1.2 Advancement of Cancer Immunotherapy
2. TYPES OF CANCER IMMUNOTHERAPY
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors
3. DYNAMICS OF GLOBAL CANCER IMMUNOTHERAPY LANDSCAPE
3.1 Favorable Developmental & Commercialization Parameters
3.2 Issues to be Resolved in Expansion of Immunotherapy Horizon
4. CANCER VACCINES: TRANSFORMING THE IMMUNOTHERAPY LANDSCAPE
4.1 Prologue of Cancer Vaccines
4.2 Cancer Vaccines in Immunotherapy
4.3 Commercialization of Cancer Vaccines
5. MONOCLONAL ANTIBODIES: NEW ERA OF IMMUNOTHERAPY
5.1 Rudiments of Monoclonal Antibodies
5.2 Advents of Monoclonal Antibodies
5.3 Commercial Aspects of Monoclonal Antibodies
6. TRAILS OF T-CELL THERAPIES
6.1 Adoptive Cell Transfer Technology
6.2 Strategies of Adoptive Cell Transfer
6.3 Commercial Aspects of Adoptive Cell Therapy
7. APPLICATION OF IMMUNE CHECKPOINT INHIBITORS IN IMMUNOTHERAPY
7.1 Prelude to Immune Checkpoint Inhibitors
7.2 Implications of Immunecheck Point Inhibitors
7.3 Commercial Aspects of Immune Checkpoint Inhibitors
8. ROLE OF IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY
8.1 Perspective of Immunomodulators
8.2 Clinical Aspects of Immunomodulators
8.3 Commercial Aspects of Immunomodulators
9. DEVELOPMENT OF ONCOLYTIC VIRAL IMMUNOTHERAPY
9.1 Concept to Oncolytic Viruses
9.2 Potential Approaches of Oncolytic Viruses
9.3 Commercial Aspects of Oncolytic Viruses
10. CYTOKINES & CANCER IMMUNOTHERAPY
10.1 Fundamentals of Cytokines
10.2 Classification of Cytokines
10.3 Commercial Aspects of Cytokines
11. INTERFERONS IN IMMUNOTHERAPY
11.1 Potentials of Interferons
11.2 Classification of Interferons
11.3 Clinical Applications of Interferons
12. INTERLEUKINS IN IMMUNOTHERAPY
12.1 Potentials of Interleukins
12.2 Clinical Applications of Interleukins
13. GM-CSF IN IMMUNOTHERAPY
13.1 Potentials of GM-CSF
13.2 Clinical Applications of GM-CSF
14. MARKET ASPECTS OF CANCER IMMUNOTHERAPY
14.1 Current Market Trends
14.2 Economic Aspects of Cancer Immunotherapy
14.3 Cancer Immunotherapy Cost by Product
15. CANCER IMMUNOTHERAPY PIPELINE OVERVIEW
15.1 By Drug Class
15.2 By Phase
15.3 By Company
15.4 By Target
15.5 By Patient Segment
16. CANCER IMMUNE CHECK POINT INHIBITORS - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
16.1 Keytruda (Pembrolizumab)
16.2 Yervoy (Ipilimumab)
16.3 Opdivo (Nivolumab)
16.4 Tecentriq (Atizolizumab)
16.5 Bavencio (Avelumab)
16.6 Imfinzi (Darlumuvab)
16.7 Libtayo (Cemiplimab)
17. CANCER MONCLONAL ANTIBODY MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
17.1 Herceptin (Trastuzumab)
17.2 Avastin (Bevacizumab)
17.3 MabThera/Rituxan (Rituximab)
17.4 Erbitux (Cetuximab)
17.5 Vectibix (Panitumab)
17.6 Arzerra (Ofatumumab)
17.7 Gazyva (Obinutuzumab)
17.8 Perjeta (Pertuzumab)
18. BISPECIFIC ANTIBODY MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
18.1 Blincyto (Blinatumomab)
19. CANCER VACCINE MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
19.1 Gardasil & Gardasil
19.2 Cervarix
19.3 Provenge (Sipuleucel – T)
19.4 Vaxira (Racotumomab)
19.5 CreaVax-RCC
20. CANCER CYTOKINES DRUGS MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
20.1 Proleukin (Aldeslukin)
20.2 Intron A (Interferon Alpha-2b)
20.3 PegIntron (PegInterferon alpha-2b)
20.4 Sylatron (Peginterferon Alpha-2b)
20.5 Betaseron (Interferon Beta-1b)
20.6 Actimmune (Interferon Gamma-1b)
20.7 Ontak (Denileukin Diftitox)
21. ONCOLYTIC VIRUS MARKET - AVAILABILITY, DOSAGE, & PRICE ANALYSIS
21.1 Imlygic
22. CAR-T Cell Therapy - Availability, Dosage, Price & Sales Analysis
22.1 Kymriah
22.2 Yescarta
23. MARKETED CANCER CELL THERAPIES DRUGS
23.1 T-Lymphocyte Cell Therapy(Immuncell-LC®)
23.2 Zalmoxis
23.3 APCEDEN For RCC
23.4 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
24. MARKETED CANCER CYTOKINES DRUGS
24.1 Aldesleukin (Proleukin®)
24.2 Denileukin Diftitox (ONTAK®)
24.3 Interferon Alpha (Multiferon®)
24.4 Interferon Alpha-2a (Roferon-A®)
24.5 Interferon Alpha-2a (Veldona®)
24.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
24.7 Interferon Alpha-2b(Intron® A)
24.8 Interferon Alpha-2b Biosimilar(Bioferon™)
24.9 Interferon Alpha-2b Biosimilar (Intalfa®)
24.10 Interferon Alpha-2b Biosimilar
24.11 Interferon Alpha-2b Biosimilar (ReliFeron®)
24.12 Interferon-Alpha-n3 (Alferon N®)
24.13 Interferon-Beta-1b (Feron®)
24.14 Interferon-Gamma (Ogamma®)
24.15 Interleukin-2 Biosimilar (Ilcass)
24.16 Teceleukin (Imunace™)
25. MARKETED CANCER VACCINES
25.1 Bladder Cancer Vaccine (PACIS®)
25.2 Bladder Cancer Vaccine
25.3 BV NSCLC
25.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
25.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
25.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
25.7 Immuvac/Cadi
25.8 Immucyst/TheraCys
25.9 Melanoma Vaccine (MVax®)
25.10 Melanoma Vaccine (Melacine®)
25.11 Racotumomab (Vaxira®)
25.12 Reniale
25.13 Sipuleucel-T (Provenge®)
25.14 Tertomotide (LucaVax)
25.15 Vitespen (Oncophage®)
26. MARKETED CANCER MONOCLONAL ANTIBODIES
26.1 Bevacizumab
26.2 Trastuzumab Emtansine
26.3 Trastuzumab Subcutaneous
26.4 Brentuximab Vedotin
26.5 Catumaxomab
26.6 Ipilimumab
26.7 Nivolumab
26.8 Pembrolizumab
26.9 Pertuzumab
26.10 Rituximab
26.11 Trastuzumab
26.12 Gemtuzumab Ozogamicin
26.13 Others
27. GLOBAL CANCER IMMUNOTHERAPY MARKET FUTURE PROSPECTS
28. COMPETITIVE LANDSCAPE
28.1 Abbvie
28.2 Advaxis
28.3 Altor BioScience
28.4 Amgen
28.5 Biogen Idec
28.6 Biogenomics
28.7 Celldex Therapeutics
28.8 Dendreon Corporation
28.9 Eli Lilly
28.10 Expression Genetics
28.11 Galena Biopharma
28.12 Genmab
28.13 Gilead Sciences
28.14 GlaxoSmithKline
28.15 ImmunoCellular Therapeutics
28.16 ImmunoGen
28.17 Inovio Pharmaceuticals
28.18 IRX Therapeutics
28.19 Merck
28.20 NeoStem Oncology
28.21 NewLink Genetics
28.22 Northwest Biotherapeutics
28.23 Novartis
28.24 Peregrine Pharmaceuticals
28.25 Pfizer
28.26 Philogen
28.27 Regulon
28.28 Roche
28.29 Seattle Genetics
28.30 ZymoGenetics
1.1 Introduction to Cancer Immunotherapy
1.2 Advancement of Cancer Immunotherapy
2. TYPES OF CANCER IMMUNOTHERAPY
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors
3. DYNAMICS OF GLOBAL CANCER IMMUNOTHERAPY LANDSCAPE
3.1 Favorable Developmental & Commercialization Parameters
3.2 Issues to be Resolved in Expansion of Immunotherapy Horizon
4. CANCER VACCINES: TRANSFORMING THE IMMUNOTHERAPY LANDSCAPE
4.1 Prologue of Cancer Vaccines
4.2 Cancer Vaccines in Immunotherapy
4.3 Commercialization of Cancer Vaccines
5. MONOCLONAL ANTIBODIES: NEW ERA OF IMMUNOTHERAPY
5.1 Rudiments of Monoclonal Antibodies
5.2 Advents of Monoclonal Antibodies
5.3 Commercial Aspects of Monoclonal Antibodies
6. TRAILS OF T-CELL THERAPIES
6.1 Adoptive Cell Transfer Technology
6.2 Strategies of Adoptive Cell Transfer
6.3 Commercial Aspects of Adoptive Cell Therapy
7. APPLICATION OF IMMUNE CHECKPOINT INHIBITORS IN IMMUNOTHERAPY
7.1 Prelude to Immune Checkpoint Inhibitors
7.2 Implications of Immunecheck Point Inhibitors
7.3 Commercial Aspects of Immune Checkpoint Inhibitors
8. ROLE OF IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY
8.1 Perspective of Immunomodulators
8.2 Clinical Aspects of Immunomodulators
8.3 Commercial Aspects of Immunomodulators
9. DEVELOPMENT OF ONCOLYTIC VIRAL IMMUNOTHERAPY
9.1 Concept to Oncolytic Viruses
9.2 Potential Approaches of Oncolytic Viruses
9.3 Commercial Aspects of Oncolytic Viruses
10. CYTOKINES & CANCER IMMUNOTHERAPY
10.1 Fundamentals of Cytokines
10.2 Classification of Cytokines
10.3 Commercial Aspects of Cytokines
11. INTERFERONS IN IMMUNOTHERAPY
11.1 Potentials of Interferons
11.2 Classification of Interferons
11.3 Clinical Applications of Interferons
12. INTERLEUKINS IN IMMUNOTHERAPY
12.1 Potentials of Interleukins
12.2 Clinical Applications of Interleukins
13. GM-CSF IN IMMUNOTHERAPY
13.1 Potentials of GM-CSF
13.2 Clinical Applications of GM-CSF
14. MARKET ASPECTS OF CANCER IMMUNOTHERAPY
14.1 Current Market Trends
14.2 Economic Aspects of Cancer Immunotherapy
14.3 Cancer Immunotherapy Cost by Product
15. CANCER IMMUNOTHERAPY PIPELINE OVERVIEW
15.1 By Drug Class
15.2 By Phase
15.3 By Company
15.4 By Target
15.5 By Patient Segment
16. CANCER IMMUNE CHECK POINT INHIBITORS - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
16.1 Keytruda (Pembrolizumab)
16.2 Yervoy (Ipilimumab)
16.3 Opdivo (Nivolumab)
16.4 Tecentriq (Atizolizumab)
16.5 Bavencio (Avelumab)
16.6 Imfinzi (Darlumuvab)
16.7 Libtayo (Cemiplimab)
17. CANCER MONCLONAL ANTIBODY MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
17.1 Herceptin (Trastuzumab)
17.2 Avastin (Bevacizumab)
17.3 MabThera/Rituxan (Rituximab)
17.4 Erbitux (Cetuximab)
17.5 Vectibix (Panitumab)
17.6 Arzerra (Ofatumumab)
17.7 Gazyva (Obinutuzumab)
17.8 Perjeta (Pertuzumab)
18. BISPECIFIC ANTIBODY MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
18.1 Blincyto (Blinatumomab)
19. CANCER VACCINE MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
19.1 Gardasil & Gardasil
19.2 Cervarix
19.3 Provenge (Sipuleucel – T)
19.4 Vaxira (Racotumomab)
19.5 CreaVax-RCC
20. CANCER CYTOKINES DRUGS MARKET - AVAILABILITY, PRICE, DOSAGE & SALES ANALYSIS
20.1 Proleukin (Aldeslukin)
20.2 Intron A (Interferon Alpha-2b)
20.3 PegIntron (PegInterferon alpha-2b)
20.4 Sylatron (Peginterferon Alpha-2b)
20.5 Betaseron (Interferon Beta-1b)
20.6 Actimmune (Interferon Gamma-1b)
20.7 Ontak (Denileukin Diftitox)
21. ONCOLYTIC VIRUS MARKET - AVAILABILITY, DOSAGE, & PRICE ANALYSIS
21.1 Imlygic
22. CAR-T Cell Therapy - Availability, Dosage, Price & Sales Analysis
22.1 Kymriah
22.2 Yescarta
23. MARKETED CANCER CELL THERAPIES DRUGS
23.1 T-Lymphocyte Cell Therapy(Immuncell-LC®)
23.2 Zalmoxis
23.3 APCEDEN For RCC
23.4 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
24. MARKETED CANCER CYTOKINES DRUGS
24.1 Aldesleukin (Proleukin®)
24.2 Denileukin Diftitox (ONTAK®)
24.3 Interferon Alpha (Multiferon®)
24.4 Interferon Alpha-2a (Roferon-A®)
24.5 Interferon Alpha-2a (Veldona®)
24.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
24.7 Interferon Alpha-2b(Intron® A)
24.8 Interferon Alpha-2b Biosimilar(Bioferon™)
24.9 Interferon Alpha-2b Biosimilar (Intalfa®)
24.10 Interferon Alpha-2b Biosimilar
24.11 Interferon Alpha-2b Biosimilar (ReliFeron®)
24.12 Interferon-Alpha-n3 (Alferon N®)
24.13 Interferon-Beta-1b (Feron®)
24.14 Interferon-Gamma (Ogamma®)
24.15 Interleukin-2 Biosimilar (Ilcass)
24.16 Teceleukin (Imunace™)
25. MARKETED CANCER VACCINES
25.1 Bladder Cancer Vaccine (PACIS®)
25.2 Bladder Cancer Vaccine
25.3 BV NSCLC
25.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
25.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
25.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
25.7 Immuvac/Cadi
25.8 Immucyst/TheraCys
25.9 Melanoma Vaccine (MVax®)
25.10 Melanoma Vaccine (Melacine®)
25.11 Racotumomab (Vaxira®)
25.12 Reniale
25.13 Sipuleucel-T (Provenge®)
25.14 Tertomotide (LucaVax)
25.15 Vitespen (Oncophage®)
26. MARKETED CANCER MONOCLONAL ANTIBODIES
26.1 Bevacizumab
26.2 Trastuzumab Emtansine
26.3 Trastuzumab Subcutaneous
26.4 Brentuximab Vedotin
26.5 Catumaxomab
26.6 Ipilimumab
26.7 Nivolumab
26.8 Pembrolizumab
26.9 Pertuzumab
26.10 Rituximab
26.11 Trastuzumab
26.12 Gemtuzumab Ozogamicin
26.13 Others
27. GLOBAL CANCER IMMUNOTHERAPY MARKET FUTURE PROSPECTS
28. COMPETITIVE LANDSCAPE
28.1 Abbvie
28.2 Advaxis
28.3 Altor BioScience
28.4 Amgen
28.5 Biogen Idec
28.6 Biogenomics
28.7 Celldex Therapeutics
28.8 Dendreon Corporation
28.9 Eli Lilly
28.10 Expression Genetics
28.11 Galena Biopharma
28.12 Genmab
28.13 Gilead Sciences
28.14 GlaxoSmithKline
28.15 ImmunoCellular Therapeutics
28.16 ImmunoGen
28.17 Inovio Pharmaceuticals
28.18 IRX Therapeutics
28.19 Merck
28.20 NeoStem Oncology
28.21 NewLink Genetics
28.22 Northwest Biotherapeutics
28.23 Novartis
28.24 Peregrine Pharmaceuticals
28.25 Pfizer
28.26 Philogen
28.27 Regulon
28.28 Roche
28.29 Seattle Genetics
28.30 ZymoGenetics
LIST OF FIGURES
Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
Figure 1-3: Potential Benefits of Cancer Immunotherapies
Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Categorization of Specific Immunotherapy
Figure 2-3: Non-Specific Cancer Immunotherapies
Figure 3-1: Favorable Cancer Immunotherapy Market Parameters
Figure 3-2: Cancer Immunotherapy Commercialization Challenges
Figure 4-1: Categorization & Function of Cancer Vaccines
Figure 4-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
Figure 4-3: Global - Cancer Vaccines Market (US$ Billion), 2018-2026
Figure 5-1: Process of Manufacturing of Monoclonal Antibody
Figure 5-2: Principles of Monoclonal Antibodies
Figure 5-3: Evolution of Monoclonal Antibody over Generations
Figure 5-4: Classification of Monoclonal Antibodies
Figure 5-5: Representation of Mechanism of Alemtuzumab
Figure 5-6: Representation of Mechanism of Ibritumomab Tiuxetan
Figure 5-7: Representation of Mechanism of Blinatumomab
Figure 5-8: Global - Market for Cancer Monoclonal Antibodies (US$ Billion), 2018-2026
Figure 6-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 6-2: Systematic Representation of Adoptive T-Cell Therapies
Figure 6-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 6-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
Figure 6-5: Mechanism of CAR Modified T-Cells
Figure 6-6: Genetically Engineered TCR for Cancer Immunotherapy
Figure 6-7: Global - Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2018-2026
Figure 7-1: Benefits of Immune Checkpoint Inhibitors
Figure 7-2: Implication of Adaptive Immune Resistance Mechanism
Figure 7-3: Mechanism of Ipilimumab
Figure 7-4: Layout of Mechanism of Nivolumab
Figure 7-5: Mechanism of Pembrolizumab
Figure 7-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2018-2026
Figure 8-1: Functions of Immunomodulators
Figure 8-2: Benefits of Immunomodulators
Figure 8-3: Layout of the Challenges of Immunomodulators
Figure 8-4: Properties of Thalidomide
Figure 8-5: Mechanism of Lenalidomide In Vivo
Figure 8-6: Mechanism of Lenalidomide in Vitro
Figure 8-7: Mechanism of Pomalidomide
Figure 8-8: Global - Immunomodulators Market for All Indications (US$ Billion), 2018-2026
Figure 9-1: Demonstration of Categorization of Oncolytic Viruses
Figure 9-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 9-3: Global - Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2018-2026
Figure 10-1: Layout of Functions Performed by Cytokine
Figure 10-2: Benefits of Cytokines in Cancer Immunotherapy
Figure 10-3: Classification of Cytokine Receptor Family
Figure 10-4: Percentage Share of the Cancer Immunotherapies by the Technology
Figure 11-1: Layout of Functions of Interferon
Figure 11-2: Classification of Interferons on the Basis of Types of Genes
Figure 11-3: General Mechanism of Interferons
Figure 11-4: Mechanism of Interferon Alfa-n3
Figure 11-5: Aspects of Peginterferon Alfa-2a
Figure 11-6: Applications of Interferon Beta 1a
Figure 11-7: Potentials of Interferon Alfa-2b
Figure 12-1: Functions of Interleukin
Figure 12-2: Potentials of Interleukins in Cancer Immunotherapy
Figure 12-3: Clinical Potentials of Proleukin
Figure 12-4: Clinical Potentials of Denileukin Diftitox
Figure 13-1: Potential Applications of GM-CSF
Figure 13-2: Mechanism of Sargramostim
Figure 14-1: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 14-2: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
Figure 14-3: Comparative Analysis of Available Cancer Treatments
Figure 14-4: Major Approved Immunotherapeutic Drugs
Figure 14-5: Annual per Patient Drug Expenditure of Immunotherapy
Figure 15-1: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-2: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-3: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-4: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-5: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-6: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-7: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-8: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2020 - 2026
Figure 15-9: Global - Cancer Immunotherapy Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-10: Global - Cancer Immunotherapy Clinical Pipeline by Company (Number), 2020 -2026
Figure 15-11: Global - Cancer Immunotherapy Clinical Pipeline by Target (Number), 2020 -2026
Figure 15-12: Global - Cancer Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 -2026
Figure 16-1: Keytruda – Patent Expiration Year by Region
Figure 16-2: Keytruda – Price for 4ml & 8ml Supply & Price per ml of Intravenous Injection (US$), January’2020
Figure 16-3: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), January’2020
Figure 16-4: Keytruda – Cost of Single and Full Treatment using Powder of Injection (US$), January’2020
Figure 16-5: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), January’2020
Figure 16-6: Keytruda – Annual Sales Value (US$ Billion), 2016, 2017 & 2018
Figure 16-7: Keytruda – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 16-8: Yervoy – US & Europe Exclusivity Expiration Year
Figure 16-9: Yervoy - Price for 10ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-10: Yervoy – Price for 40ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-11: Yervoy – Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (Weeks), January’2020
Figure 16-12: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (US$), January’2020
Figure 16-13: Yervoy – Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), January’2020
Figure 16-14: Yervoy – Duration of Single Treatment Cycle & Full Treatment in Combinational Therapy (Weeks), January’2020
Figure 16-15: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment in Combinational Therapy (US$), January’2020
Figure 16-16: Yervoy – Annual Sales Value (US$ Billion), 2016-2018
Figure 16-17: Yervoy – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-19: Yervoy – US v/s Rest of World Sales Share (%), Q1-Q3, 2019
Figure 16-20: Opdivo - Patent Expiration Year by Region
Figure 16-21: Opdivo - Price for 4ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-22: Opdivo - Price for 10 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-23: Opdivo - Price for 20 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-24: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), January’2020
Figure 16-25: Opdivo Combination – Dose for Management of Melanoma & Renal Cell Carcinoma (mg/3 Weeks)), January’2020
Figure 16-26: Opdivo – Annual Sales Value (US$ Billion), 2016 - 2018
Figure 16-27: Opdivo – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 16-28: US - Opdivo – Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
Figure 16-29: Opdivo – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 16-30: Tecentriq - Price for 14ml Supply & Price per ml of 840mg/14ml Intravenous Injection (US$), January’2020
Figure 16-31: Tecentriq - Price for 20ml Supply & Price per ml of 1200mg/20ml Intravenous Injection (US$), January’2020
Figure 16-32: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), January’2020
Figure 16-33: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), January’2020
Figure 16-34: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), January’2020
Figure 16-35: Tecentriq – Annual Sales Value (US$/CHF Million), 2017 & 2018
Figure 16-36: Tecentriq – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-37: Tecentriq – Quarterly Sales Value (US$ Million), 2018
Figure 16-38: Tecentriq – Sales Value of US v/s ROW (US$ Billion), Q1-Q3, 2019
Figure 16-39: Tecentriq – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 16-40: Bavencio - Price for 10ml Supply & Price per ml of 20mg/ml Intravenous Injection (US$), January’2020
Figure 16-41: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US$), January’2020
Figure 16-42: Bavencio – Annual Sales Value (US$/EUR Million), 2017 & 2018
Figure 16-43: Bavencio – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-44: Imfinzi – FDA Approval & Patent Expiration Year
Figure 16-45: Imfinzi – Price for a Supply of 2.4ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-46: Imfinzi – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-47: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of NSCLC (US$), January’2020
Figure 16-48: Imfinzi – Annual Sales Value (US$ Million), 2017 & 2018
Figure 16-49: Imfinzi – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-50: Libtayo – Price for a Supply of 7ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-51: Libtayo – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January’2020
Figure 16-52: Libtayo – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-53: US - Libtayo Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-54: Libtayo – 9 Month Sales Share – US v/s Rest of World (%), Q1-Q3, 2019
Figure 16-55: Libtayo – 9 Month Sales of US v/s Rest of World (US$ Million), Q1-Q3, 2019
Figure 17-1: Herceptin – Approval Year by Cancer Type
Figure 17-2: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), January’2020
Figure 17-3: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), January’2020
Figure 17-4: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), January’2020
Figure 17-5: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), January’2020
Figure 17-6: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), January’2020
Figure 17-7: Herceptin – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-8: Herceptin – Quarterly Sales Value (US$/CHF Billion), Q1-Q4, 2018
Figure 17-9: Herceptin – Quarterly Sales Value (US$/CHF Billion), Q1-Q3, 2019
Figure 17-10: US - Herceptin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-11: Herceptin – Sales Value – US v/s ROW (US$ Billion), 2018
Figure 17-12: Herceptin –Sales Share by Region (%), 2018
Figure 17-13: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), January’2020
Figure 17-14: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), January’2020
Figure 17-15: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), January’2020
Figure 17-16: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January’2020
Figure 17-17: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), January’2020
Figure 17-18: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January’2020
Figure 17-19: Avastin – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-20: Avastin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-21: US - Avastin – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 17-22: Avastin – 9 Month Sales Share by Region (US$ Billion), Q1-Q3, 2019
Figure 17-23: Avastin – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 17-24: Rituxan – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-25: Rituxan – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-26: Rituxan – Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-27: Rituxan – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL (US$), January’2020
Figure 17-28: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for Non-Progressing CD20+ B-Cell NHL (US$), January’2020
Figure 17-29: Rituxan – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-30: Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-31: US - Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
Figure 17-32: Avastin – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 17-33: Rituxan – 9 Month Sales Share by Region (CHF/US$ Billion)), Q1-Q3, 2019
Figure 17-34: Rituxan – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 17-35: Erbitux - Approval Year by Cancer Type
Figure 17-36: Erbitux - Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-37: Erbitux - Price for a Supply of 100 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-38: Erbitux – Initial & Maintenance Dose for Colorectal, Head & Neck Cancer Treatment (mg/m2), January’2020
Figure 17-39: Erbitux – Average Cost of Initial Dose, Maintenance Dose & Cost of Annual Treatment (US$), January’2020
Figure 17-40: Erbitux – Annual Sales Value (US$ Million), 2016 - 2018
Figure 17-41: US - Erbitux Sales Value (US$ Million), 2017 & 2018
Figure 17-42: Erbitux - Sales Share US v/s Rest of World (%), 2018
Figure 17-43: Erbitux – Quarterly Sales Value (US$ Million), Q1-Q3, 2017 & 2018
Figure 17-44: Vectibix - FDA Approval & Patent Expiration Year
Figure 17-45: Vectibix – Price for a Supply of 5 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-46: Vectibix – Price for a Supply of 20 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-47: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), January’2020
Figure 17-48: Vectibix – Annual Sales Value (US$ Million), 2015 - 2018
Figure 17-49: Vectibix - Sales Share US v/s Rest of World (%), 2018
Figure 17-50: Vectibix – Quarterly Sales Value (US$ Million), Q1 – Q3, 2018 & 2019
Figure 17-51: Vectibix – 9 Month Sales Share US v/s Rest of World (%), Q1 – Q3, 2019
Figure 17-52: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-53: Arzerra – Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-54: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), January’2020
Figure 17-55: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), January’2020
Figure 17-56: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), January’2020
Figure 17-57: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), January’2020
Figure 17-58: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), January’2020
Figure 17-59: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), January’2020
Figure 17-60: Arzerra – Treatment Duration for Refractory CLL (Weeks), January’2020
Figure 17-61: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), January’2020
Figure 17-62: Gazyva – Approval Year by Cancer Type
Figure 17-63: Gazyva – Price for 40ml Supply & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-64: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), January’2020
Figure 17-65: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week), January’2020
Figure 17-66: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), January’2020
Figure 17-67: Gazyva – Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week), January’2020
Figure 17-68: Gazyva – Minimum & Maximum Treatment Cost of Follicular Lymphoma (US$), January’2020
Figure 17-69: Gazyva – Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), January’2020
Figure 17-70: Gazyva – Cost of Single Treatment Cycle & Full Treatment using Monotherapy (US$), January’2020
Figure 17-71: Gazyva – Annual Sales Value (US$/CHF Million), 2016 - 2018
Figure 17-72: Gazyva – Quarterly Sales Value (US$/CHF Million), 2018
Figure 17-73: Gazyva – Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
Figure 17-74: US - Gazyva – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 17-75: Gazyva – 9 Month Sales Share by Region (CHF/US$ Million), Q1-Q3, 2019
Figure 17-76: Gazyva – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 17-77: Perjeta - Approval Year by Cancer Type
Figure 17-78: Perjeta – Patent Expiration Year – US & Europe
Figure 17-79: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-80: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/3 weeks), January’2020
Figure 17-81: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US$), January’2020
Figure 17-82: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), January’2020
Figure 17-83: Perjeta – Annual Sales Value (US$/CHF Billion), 2016 - 2018
Figure 17-84: Perjeta – Quarterly Sales Value (US$/CHF Million), 2018
Figure 17-85: Perjeta – Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
Figure 17-86: US - Perjeta – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 17-87: Perjeta – Sales Value by Region (US$/CHF Million), Q1 – Q3, 2019
Figure 17-88: Perjeta – Sales Value by Region, Q1 – Q3, 2019
Figure 18-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, January’2020
Figure 18-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , January’2020
Figure 18-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), January’2020
Figure 18-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, January’2020
Figure 18-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), January’2020
Figure 18-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), January’2020
Figure 18-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), January’2020
Figure 18-8: Blincyto - Sales Value (US$ Million), 2015 - 2018
Figure 18-9: US - Blincyto Sales Value (US$ Million), 2016 - 2018
Figure 18-10: Blincyto - Quarterly Sales Value (US$ Million), 2018
Figure 18-11: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
Figure 18-12: Blincyto - Quarterly Sales Value (US$ Million), Q1 – Q3, 2018 & 2019
Figure 18-13: Blincyto - US & Rest of World Sales Value (US$ Million), Q1 - Q3, 2019
Figure 18-14: Blincyto - US v/s ROW Share in 9 Month Sales Value (%), 2019
Figure 19-1: Gardasil & Gardasil 9 – FDA Approval Year
Figure 19-2: Gardasil – Patent Expiration Year of US & Europe
Figure 19-3: Gardasil 9 – US & Europe Patent Expiration Year
Figure 19-4: Gardasil – Price for 0.5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-5: Gardasil – Price for 3ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-6: Gardasil – Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-7: Gardasil 9 – Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-8: Gardasil – Cost of Single Dose & Cost of Full Course (US$), January’2020
Figure 19-9: Gardasil 9 – Cost of Single Dose & Cost of Full Course (US$), January’2020
Figure 19-10: Gardasil & Gardasil 9 – Annual Sales Value (US$ Million), 2016, 2017 & 2018
Figure 19-11: Gardasil and Gardasil 9 – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 19-12: Cervarix – US & Europe Patent Expiration Year
Figure 19-13: Cervarix – Cost of Single Dose & Cost of Full Course (US$/GBP Million), January’2020
Figure 19-14: Cervarix – Annual Sales Value (US$/GBP Million), 2016 - 2018
Figure 19-15: Cervarix - Sales Share Europe v/s Rest of World (%), 2018
Figure 19-16: Cervarix – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 19-17: Cervarix - Europe v/s Rest of World Sales Share (%), Q1-Q3, 2019
Figure 19-18: Provenge – Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-19: Provenge – Cost of Single Treatment Cycle & Cost of Full Treatment (US$), January’2020
Figure 19-20: Vaxira – Cost for Single Injection & Single Dose (US$), January’2020
Figure 19-21: Vaxira – Number of Doses in Induction & Maintenance Phase, January’2020
Figure 19-22: Vaxira – Dose Interval in Induction & Maintenance Phase (Week), January’2020
Figure 19-23: Vaxira – Duration of Induction & Maintenance Phase (Weeks), January’2020
Figure 19-24: Vaxira – Cost of Induction & Maintenance Phase (US$), January’2020
Figure 19-25: CreaVax-RCC – Duration of Single Cycle & Full Treatment (Weeks), January’2020
Figure 20-1: Proleukin – Duration of Treatment by Phases (Hours), January’2020
Figure 20-2: Proleukin - Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), January’2020
Figure 20-3: Proleukin – Number of Doses for Metastatic Renal Cell Carcinoma & Melanoma, January’2020
Figure 20-4: Proleukin – Average Cost For Treatment of Metastatic RCC & Melanoma, January’2020
Figure 20-5: Intron A – Price for a Supply of 10, 18 & 50 Million IU Powder for Injection (US$), January’2020
Figure 20-6: Intron A – Price for a Supply of 6 & 10 Million IU/ml Intravenous Solution (US$), January’2020
Figure 20-7: Intron A – Average Cost of Single Treatment Cycle for Hairy Cell Leukemia using Powder & Solution for Injection (US$), January’2020
Figure 20-8: Intron A – Average Cost of Full Treatment for Course Hairy Cell Leukemia using Powder & Solution for Injection (US$), January’2020
Figure 20-9: Intron A – Dose for Induction & Maintenance Phase for Malignant Melanoma Treatment (Million IU/m2), January’2020
Figure 20-10: Intron A – Duration of Induction & Maintenance Phase for Malignant Melanoma Treatment (Weeks), January’2020
Figure 20-11: Intron A – Duration of Single Treatment Cycle & Full Treatment of Follicular Lymphoma (Weeks), January’2020
Figure 20-12: PegIntron - Patent Expiration Year by Region
Figure 20-13: PegIntron – Price for 4 Powder Supply & Price Per Unit of 120mg Powder for Injection (US$), January’2020
Figure 20-14: PegIntron Monotherapy – Dose by Weight of Patient (mcg), January’2020
Figure 20-15: PegIntron Monotherapy – Reduced Dose by Weight of Patient (mcg), January’2020
Figure 20-16: Pegintron Combination – Duration of Treatment by Genotype (Weeks), January’2020
Figure 20-17: Sylatron – Price for 4 Powder Supply & Price per Unit of 120mg Powder for Injection (US$), January’2020
Figure 20-18: Sylatron – Initial & Maintenance Dose (mcg/Kg/Week), January’2020
Figure 20-19: Sylatron – Duration of Initial Phase, Maintenance Phase & Full Treatment (Weeks), January’2020
Figure 20-20: Sylatron - Average Cost of Single Initial Dose & Full Initial Phase (US$), January’2020
Figure 20-21: Sylatron - Average Cost of Single Maintenence Dose, Annual Maintenance Cost & Full Maintenance Phase (US$), January’2020
Figure 20-22: Betaseron – Price for 14 Powder Supply & Price per Unit of 0.3mg Powder for Injection (US$), January’2020
Figure 20-23: Betaseron – Dose Incrimination Pattern (mg/48 hours), January’2020
Figure 20-24: Betaseron – Sales Value (US$/EUR Million), 2017 & 2018
Figure 20-25: Betaseron – US v/s ROW Sales Value (%), 2018
Figure 20-26: Betaseron – Quarterly Sales Value (US$/EUR Million), 2018
Figure 20-27: Betaseron – Quarterly Sales Value (US$/EUR Million), Q1 – Q3, 2019
Figure 20-28: Actimmune - FDA Approval & Patent Expiration Year
Figure 20-29: Actimmune – Price for 6ml Supply, 1 ml & price for Single Vial of 0.5ml Subcutaneous Solution (US$), January’ 2020
Figure 20-30: Actimmune – Average Cost of Single Dose & Single Treatment Cycle (US$), January’ 2020
Figure 20-31: Actimmune – Sales Value (US$/EUR Million), 2017 & 2018
Figure 20-32: Actimmune – Quarterly Sales Value (US$/EUR Million), Q1 – Q3, 2019
Figure 20-33: Ontack – Duration of Single Treatment Cycle & Full Treatment (Weeks), January’ 2020
Figure 20-34: Ontack – Average Minimum & Maximum Cost of Single Dose Administration (US$), January’ 2020
Figure 20-35: Ontack – Average Minimum & Maximum Cost of Single Treatment Cycle (US$), January’ 2020
Figure 21-1: Imlygic – US & European Patent Expiration Year
Figure 21-2: Imlygic – Price of 1 Million PUF/ml & 100 Million PUF/ml Injectable Suspension (US$), January’2020
Figure 21-3: Imlygic – Concentration of Dose for Initial Treatment Cycle & Subsequent Treatment Cycle (Million PUF/ml), January’2020
Figure 21-4: Imlygic – Average Price of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US$), January’2020
Figure 21-5: Imlygic – Volume Administered by Size of Lesion (ml), January’2020
Figure 22-1: Kymriah – FDA approval Year by Cancer Type
Figure 22-2: Kymriah – Number of Patents in US, Europe & Japan
Figure 22-3: Kymriah – Cost of Advanced Lymphoma Treatment (US$ 000’), Janouary’2020
Figure 22-4: Kymriah – Cost of Acute Lymphoblastic Leukemia Treatment (US$ 000’), Janouary’2020
Figure 22-5: Kymriah - Sales Value (US$ Million), 2017 & 2018
Figure 22-6: Kymriah – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 22-7: Yescarta - FDA Approval & US Patent Expiration Year
Figure 22-8: Yescarta - Cost of Advanced Lymphoma Treatment (US$ 000’), Janouary’2020
Figure 22-9: Yescarta - Sales Value (US$ Million), 2017 & 2018
Figure 22-10: Yescarta – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 28-1: Advaxis Clinical Pipeline
Figure 28-2: Celldex Therapeutics Clinical Pipeline
Figure 28-3: Expression Genetics Clinical Pipeline
Figure 28-4: Galena Biopharma Clinical Pipeline
Figure 28-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 28-6: ImmunoGen Clinical Pipeline
Figure 28-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 28-8: NewLink Genetics Corporation Clinical Pipeline
Figure 28-9: Northwest Biotherapeutics Clinical Pipeline
Figure 28-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 28-11: Philogen Clinical Pipeline
Figure 28-12: Seattle Genetics Clinical Pipeline
Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
Figure 1-3: Potential Benefits of Cancer Immunotherapies
Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Categorization of Specific Immunotherapy
Figure 2-3: Non-Specific Cancer Immunotherapies
Figure 3-1: Favorable Cancer Immunotherapy Market Parameters
Figure 3-2: Cancer Immunotherapy Commercialization Challenges
Figure 4-1: Categorization & Function of Cancer Vaccines
Figure 4-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
Figure 4-3: Global - Cancer Vaccines Market (US$ Billion), 2018-2026
Figure 5-1: Process of Manufacturing of Monoclonal Antibody
Figure 5-2: Principles of Monoclonal Antibodies
Figure 5-3: Evolution of Monoclonal Antibody over Generations
Figure 5-4: Classification of Monoclonal Antibodies
Figure 5-5: Representation of Mechanism of Alemtuzumab
Figure 5-6: Representation of Mechanism of Ibritumomab Tiuxetan
Figure 5-7: Representation of Mechanism of Blinatumomab
Figure 5-8: Global - Market for Cancer Monoclonal Antibodies (US$ Billion), 2018-2026
Figure 6-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 6-2: Systematic Representation of Adoptive T-Cell Therapies
Figure 6-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 6-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
Figure 6-5: Mechanism of CAR Modified T-Cells
Figure 6-6: Genetically Engineered TCR for Cancer Immunotherapy
Figure 6-7: Global - Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2018-2026
Figure 7-1: Benefits of Immune Checkpoint Inhibitors
Figure 7-2: Implication of Adaptive Immune Resistance Mechanism
Figure 7-3: Mechanism of Ipilimumab
Figure 7-4: Layout of Mechanism of Nivolumab
Figure 7-5: Mechanism of Pembrolizumab
Figure 7-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2018-2026
Figure 8-1: Functions of Immunomodulators
Figure 8-2: Benefits of Immunomodulators
Figure 8-3: Layout of the Challenges of Immunomodulators
Figure 8-4: Properties of Thalidomide
Figure 8-5: Mechanism of Lenalidomide In Vivo
Figure 8-6: Mechanism of Lenalidomide in Vitro
Figure 8-7: Mechanism of Pomalidomide
Figure 8-8: Global - Immunomodulators Market for All Indications (US$ Billion), 2018-2026
Figure 9-1: Demonstration of Categorization of Oncolytic Viruses
Figure 9-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 9-3: Global - Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2018-2026
Figure 10-1: Layout of Functions Performed by Cytokine
Figure 10-2: Benefits of Cytokines in Cancer Immunotherapy
Figure 10-3: Classification of Cytokine Receptor Family
Figure 10-4: Percentage Share of the Cancer Immunotherapies by the Technology
Figure 11-1: Layout of Functions of Interferon
Figure 11-2: Classification of Interferons on the Basis of Types of Genes
Figure 11-3: General Mechanism of Interferons
Figure 11-4: Mechanism of Interferon Alfa-n3
Figure 11-5: Aspects of Peginterferon Alfa-2a
Figure 11-6: Applications of Interferon Beta 1a
Figure 11-7: Potentials of Interferon Alfa-2b
Figure 12-1: Functions of Interleukin
Figure 12-2: Potentials of Interleukins in Cancer Immunotherapy
Figure 12-3: Clinical Potentials of Proleukin
Figure 12-4: Clinical Potentials of Denileukin Diftitox
Figure 13-1: Potential Applications of GM-CSF
Figure 13-2: Mechanism of Sargramostim
Figure 14-1: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 14-2: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
Figure 14-3: Comparative Analysis of Available Cancer Treatments
Figure 14-4: Major Approved Immunotherapeutic Drugs
Figure 14-5: Annual per Patient Drug Expenditure of Immunotherapy
Figure 15-1: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-2: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-3: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-4: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-5: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-6: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-7: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-8: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2020 - 2026
Figure 15-9: Global - Cancer Immunotherapy Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-10: Global - Cancer Immunotherapy Clinical Pipeline by Company (Number), 2020 -2026
Figure 15-11: Global - Cancer Immunotherapy Clinical Pipeline by Target (Number), 2020 -2026
Figure 15-12: Global - Cancer Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 -2026
Figure 16-1: Keytruda – Patent Expiration Year by Region
Figure 16-2: Keytruda – Price for 4ml & 8ml Supply & Price per ml of Intravenous Injection (US$), January’2020
Figure 16-3: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), January’2020
Figure 16-4: Keytruda – Cost of Single and Full Treatment using Powder of Injection (US$), January’2020
Figure 16-5: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), January’2020
Figure 16-6: Keytruda – Annual Sales Value (US$ Billion), 2016, 2017 & 2018
Figure 16-7: Keytruda – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 16-8: Yervoy – US & Europe Exclusivity Expiration Year
Figure 16-9: Yervoy - Price for 10ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-10: Yervoy – Price for 40ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-11: Yervoy – Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (Weeks), January’2020
Figure 16-12: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (US$), January’2020
Figure 16-13: Yervoy – Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), January’2020
Figure 16-14: Yervoy – Duration of Single Treatment Cycle & Full Treatment in Combinational Therapy (Weeks), January’2020
Figure 16-15: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment in Combinational Therapy (US$), January’2020
Figure 16-16: Yervoy – Annual Sales Value (US$ Billion), 2016-2018
Figure 16-17: Yervoy – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-19: Yervoy – US v/s Rest of World Sales Share (%), Q1-Q3, 2019
Figure 16-20: Opdivo - Patent Expiration Year by Region
Figure 16-21: Opdivo - Price for 4ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-22: Opdivo - Price for 10 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-23: Opdivo - Price for 20 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-24: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), January’2020
Figure 16-25: Opdivo Combination – Dose for Management of Melanoma & Renal Cell Carcinoma (mg/3 Weeks)), January’2020
Figure 16-26: Opdivo – Annual Sales Value (US$ Billion), 2016 - 2018
Figure 16-27: Opdivo – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 16-28: US - Opdivo – Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
Figure 16-29: Opdivo – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 16-30: Tecentriq - Price for 14ml Supply & Price per ml of 840mg/14ml Intravenous Injection (US$), January’2020
Figure 16-31: Tecentriq - Price for 20ml Supply & Price per ml of 1200mg/20ml Intravenous Injection (US$), January’2020
Figure 16-32: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), January’2020
Figure 16-33: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), January’2020
Figure 16-34: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), January’2020
Figure 16-35: Tecentriq – Annual Sales Value (US$/CHF Million), 2017 & 2018
Figure 16-36: Tecentriq – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-37: Tecentriq – Quarterly Sales Value (US$ Million), 2018
Figure 16-38: Tecentriq – Sales Value of US v/s ROW (US$ Billion), Q1-Q3, 2019
Figure 16-39: Tecentriq – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 16-40: Bavencio - Price for 10ml Supply & Price per ml of 20mg/ml Intravenous Injection (US$), January’2020
Figure 16-41: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US$), January’2020
Figure 16-42: Bavencio – Annual Sales Value (US$/EUR Million), 2017 & 2018
Figure 16-43: Bavencio – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-44: Imfinzi – FDA Approval & Patent Expiration Year
Figure 16-45: Imfinzi – Price for a Supply of 2.4ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-46: Imfinzi – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-47: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of NSCLC (US$), January’2020
Figure 16-48: Imfinzi – Annual Sales Value (US$ Million), 2017 & 2018
Figure 16-49: Imfinzi – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-50: Libtayo – Price for a Supply of 7ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-51: Libtayo – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January’2020
Figure 16-52: Libtayo – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-53: US - Libtayo Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-54: Libtayo – 9 Month Sales Share – US v/s Rest of World (%), Q1-Q3, 2019
Figure 16-55: Libtayo – 9 Month Sales of US v/s Rest of World (US$ Million), Q1-Q3, 2019
Figure 17-1: Herceptin – Approval Year by Cancer Type
Figure 17-2: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), January’2020
Figure 17-3: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), January’2020
Figure 17-4: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), January’2020
Figure 17-5: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), January’2020
Figure 17-6: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), January’2020
Figure 17-7: Herceptin – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-8: Herceptin – Quarterly Sales Value (US$/CHF Billion), Q1-Q4, 2018
Figure 17-9: Herceptin – Quarterly Sales Value (US$/CHF Billion), Q1-Q3, 2019
Figure 17-10: US - Herceptin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-11: Herceptin – Sales Value – US v/s ROW (US$ Billion), 2018
Figure 17-12: Herceptin –Sales Share by Region (%), 2018
Figure 17-13: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), January’2020
Figure 17-14: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), January’2020
Figure 17-15: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), January’2020
Figure 17-16: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January’2020
Figure 17-17: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), January’2020
Figure 17-18: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January’2020
Figure 17-19: Avastin – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-20: Avastin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-21: US - Avastin – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 17-22: Avastin – 9 Month Sales Share by Region (US$ Billion), Q1-Q3, 2019
Figure 17-23: Avastin – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 17-24: Rituxan – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-25: Rituxan – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-26: Rituxan – Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-27: Rituxan – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL (US$), January’2020
Figure 17-28: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for Non-Progressing CD20+ B-Cell NHL (US$), January’2020
Figure 17-29: Rituxan – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-30: Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-31: US - Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
Figure 17-32: Avastin – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 17-33: Rituxan – 9 Month Sales Share by Region (CHF/US$ Billion)), Q1-Q3, 2019
Figure 17-34: Rituxan – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 17-35: Erbitux - Approval Year by Cancer Type
Figure 17-36: Erbitux - Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-37: Erbitux - Price for a Supply of 100 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-38: Erbitux – Initial & Maintenance Dose for Colorectal, Head & Neck Cancer Treatment (mg/m2), January’2020
Figure 17-39: Erbitux – Average Cost of Initial Dose, Maintenance Dose & Cost of Annual Treatment (US$), January’2020
Figure 17-40: Erbitux – Annual Sales Value (US$ Million), 2016 - 2018
Figure 17-41: US - Erbitux Sales Value (US$ Million), 2017 & 2018
Figure 17-42: Erbitux - Sales Share US v/s Rest of World (%), 2018
Figure 17-43: Erbitux – Quarterly Sales Value (US$ Million), Q1-Q3, 2017 & 2018
Figure 17-44: Vectibix - FDA Approval & Patent Expiration Year
Figure 17-45: Vectibix – Price for a Supply of 5 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-46: Vectibix – Price for a Supply of 20 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-47: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), January’2020
Figure 17-48: Vectibix – Annual Sales Value (US$ Million), 2015 - 2018
Figure 17-49: Vectibix - Sales Share US v/s Rest of World (%), 2018
Figure 17-50: Vectibix – Quarterly Sales Value (US$ Million), Q1 – Q3, 2018 & 2019
Figure 17-51: Vectibix – 9 Month Sales Share US v/s Rest of World (%), Q1 – Q3, 2019
Figure 17-52: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-53: Arzerra – Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-54: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), January’2020
Figure 17-55: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), January’2020
Figure 17-56: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), January’2020
Figure 17-57: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), January’2020
Figure 17-58: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), January’2020
Figure 17-59: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), January’2020
Figure 17-60: Arzerra – Treatment Duration for Refractory CLL (Weeks), January’2020
Figure 17-61: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), January’2020
Figure 17-62: Gazyva – Approval Year by Cancer Type
Figure 17-63: Gazyva – Price for 40ml Supply & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-64: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), January’2020
Figure 17-65: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week), January’2020
Figure 17-66: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), January’2020
Figure 17-67: Gazyva – Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week), January’2020
Figure 17-68: Gazyva – Minimum & Maximum Treatment Cost of Follicular Lymphoma (US$), January’2020
Figure 17-69: Gazyva – Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), January’2020
Figure 17-70: Gazyva – Cost of Single Treatment Cycle & Full Treatment using Monotherapy (US$), January’2020
Figure 17-71: Gazyva – Annual Sales Value (US$/CHF Million), 2016 - 2018
Figure 17-72: Gazyva – Quarterly Sales Value (US$/CHF Million), 2018
Figure 17-73: Gazyva – Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
Figure 17-74: US - Gazyva – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 17-75: Gazyva – 9 Month Sales Share by Region (CHF/US$ Million), Q1-Q3, 2019
Figure 17-76: Gazyva – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 17-77: Perjeta - Approval Year by Cancer Type
Figure 17-78: Perjeta – Patent Expiration Year – US & Europe
Figure 17-79: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-80: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/3 weeks), January’2020
Figure 17-81: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US$), January’2020
Figure 17-82: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), January’2020
Figure 17-83: Perjeta – Annual Sales Value (US$/CHF Billion), 2016 - 2018
Figure 17-84: Perjeta – Quarterly Sales Value (US$/CHF Million), 2018
Figure 17-85: Perjeta – Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
Figure 17-86: US - Perjeta – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 17-87: Perjeta – Sales Value by Region (US$/CHF Million), Q1 – Q3, 2019
Figure 17-88: Perjeta – Sales Value by Region, Q1 – Q3, 2019
Figure 18-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, January’2020
Figure 18-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , January’2020
Figure 18-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), January’2020
Figure 18-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, January’2020
Figure 18-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), January’2020
Figure 18-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), January’2020
Figure 18-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), January’2020
Figure 18-8: Blincyto - Sales Value (US$ Million), 2015 - 2018
Figure 18-9: US - Blincyto Sales Value (US$ Million), 2016 - 2018
Figure 18-10: Blincyto - Quarterly Sales Value (US$ Million), 2018
Figure 18-11: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
Figure 18-12: Blincyto - Quarterly Sales Value (US$ Million), Q1 – Q3, 2018 & 2019
Figure 18-13: Blincyto - US & Rest of World Sales Value (US$ Million), Q1 - Q3, 2019
Figure 18-14: Blincyto - US v/s ROW Share in 9 Month Sales Value (%), 2019
Figure 19-1: Gardasil & Gardasil 9 – FDA Approval Year
Figure 19-2: Gardasil – Patent Expiration Year of US & Europe
Figure 19-3: Gardasil 9 – US & Europe Patent Expiration Year
Figure 19-4: Gardasil – Price for 0.5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-5: Gardasil – Price for 3ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-6: Gardasil – Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-7: Gardasil 9 – Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-8: Gardasil – Cost of Single Dose & Cost of Full Course (US$), January’2020
Figure 19-9: Gardasil 9 – Cost of Single Dose & Cost of Full Course (US$), January’2020
Figure 19-10: Gardasil & Gardasil 9 – Annual Sales Value (US$ Million), 2016, 2017 & 2018
Figure 19-11: Gardasil and Gardasil 9 – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 19-12: Cervarix – US & Europe Patent Expiration Year
Figure 19-13: Cervarix – Cost of Single Dose & Cost of Full Course (US$/GBP Million), January’2020
Figure 19-14: Cervarix – Annual Sales Value (US$/GBP Million), 2016 - 2018
Figure 19-15: Cervarix - Sales Share Europe v/s Rest of World (%), 2018
Figure 19-16: Cervarix – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 19-17: Cervarix - Europe v/s Rest of World Sales Share (%), Q1-Q3, 2019
Figure 19-18: Provenge – Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-19: Provenge – Cost of Single Treatment Cycle & Cost of Full Treatment (US$), January’2020
Figure 19-20: Vaxira – Cost for Single Injection & Single Dose (US$), January’2020
Figure 19-21: Vaxira – Number of Doses in Induction & Maintenance Phase, January’2020
Figure 19-22: Vaxira – Dose Interval in Induction & Maintenance Phase (Week), January’2020
Figure 19-23: Vaxira – Duration of Induction & Maintenance Phase (Weeks), January’2020
Figure 19-24: Vaxira – Cost of Induction & Maintenance Phase (US$), January’2020
Figure 19-25: CreaVax-RCC – Duration of Single Cycle & Full Treatment (Weeks), January’2020
Figure 20-1: Proleukin – Duration of Treatment by Phases (Hours), January’2020
Figure 20-2: Proleukin - Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), January’2020
Figure 20-3: Proleukin – Number of Doses for Metastatic Renal Cell Carcinoma & Melanoma, January’2020
Figure 20-4: Proleukin – Average Cost For Treatment of Metastatic RCC & Melanoma, January’2020
Figure 20-5: Intron A – Price for a Supply of 10, 18 & 50 Million IU Powder for Injection (US$), January’2020
Figure 20-6: Intron A – Price for a Supply of 6 & 10 Million IU/ml Intravenous Solution (US$), January’2020
Figure 20-7: Intron A – Average Cost of Single Treatment Cycle for Hairy Cell Leukemia using Powder & Solution for Injection (US$), January’2020
Figure 20-8: Intron A – Average Cost of Full Treatment for Course Hairy Cell Leukemia using Powder & Solution for Injection (US$), January’2020
Figure 20-9: Intron A – Dose for Induction & Maintenance Phase for Malignant Melanoma Treatment (Million IU/m2), January’2020
Figure 20-10: Intron A – Duration of Induction & Maintenance Phase for Malignant Melanoma Treatment (Weeks), January’2020
Figure 20-11: Intron A – Duration of Single Treatment Cycle & Full Treatment of Follicular Lymphoma (Weeks), January’2020
Figure 20-12: PegIntron - Patent Expiration Year by Region
Figure 20-13: PegIntron – Price for 4 Powder Supply & Price Per Unit of 120mg Powder for Injection (US$), January’2020
Figure 20-14: PegIntron Monotherapy – Dose by Weight of Patient (mcg), January’2020
Figure 20-15: PegIntron Monotherapy – Reduced Dose by Weight of Patient (mcg), January’2020
Figure 20-16: Pegintron Combination – Duration of Treatment by Genotype (Weeks), January’2020
Figure 20-17: Sylatron – Price for 4 Powder Supply & Price per Unit of 120mg Powder for Injection (US$), January’2020
Figure 20-18: Sylatron – Initial & Maintenance Dose (mcg/Kg/Week), January’2020
Figure 20-19: Sylatron – Duration of Initial Phase, Maintenance Phase & Full Treatment (Weeks), January’2020
Figure 20-20: Sylatron - Average Cost of Single Initial Dose & Full Initial Phase (US$), January’2020
Figure 20-21: Sylatron - Average Cost of Single Maintenence Dose, Annual Maintenance Cost & Full Maintenance Phase (US$), January’2020
Figure 20-22: Betaseron – Price for 14 Powder Supply & Price per Unit of 0.3mg Powder for Injection (US$), January’2020
Figure 20-23: Betaseron – Dose Incrimination Pattern (mg/48 hours), January’2020
Figure 20-24: Betaseron – Sales Value (US$/EUR Million), 2017 & 2018
Figure 20-25: Betaseron – US v/s ROW Sales Value (%), 2018
Figure 20-26: Betaseron – Quarterly Sales Value (US$/EUR Million), 2018
Figure 20-27: Betaseron – Quarterly Sales Value (US$/EUR Million), Q1 – Q3, 2019
Figure 20-28: Actimmune - FDA Approval & Patent Expiration Year
Figure 20-29: Actimmune – Price for 6ml Supply, 1 ml & price for Single Vial of 0.5ml Subcutaneous Solution (US$), January’ 2020
Figure 20-30: Actimmune – Average Cost of Single Dose & Single Treatment Cycle (US$), January’ 2020
Figure 20-31: Actimmune – Sales Value (US$/EUR Million), 2017 & 2018
Figure 20-32: Actimmune – Quarterly Sales Value (US$/EUR Million), Q1 – Q3, 2019
Figure 20-33: Ontack – Duration of Single Treatment Cycle & Full Treatment (Weeks), January’ 2020
Figure 20-34: Ontack – Average Minimum & Maximum Cost of Single Dose Administration (US$), January’ 2020
Figure 20-35: Ontack – Average Minimum & Maximum Cost of Single Treatment Cycle (US$), January’ 2020
Figure 21-1: Imlygic – US & European Patent Expiration Year
Figure 21-2: Imlygic – Price of 1 Million PUF/ml & 100 Million PUF/ml Injectable Suspension (US$), January’2020
Figure 21-3: Imlygic – Concentration of Dose for Initial Treatment Cycle & Subsequent Treatment Cycle (Million PUF/ml), January’2020
Figure 21-4: Imlygic – Average Price of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US$), January’2020
Figure 21-5: Imlygic – Volume Administered by Size of Lesion (ml), January’2020
Figure 22-1: Kymriah – FDA approval Year by Cancer Type
Figure 22-2: Kymriah – Number of Patents in US, Europe & Japan
Figure 22-3: Kymriah – Cost of Advanced Lymphoma Treatment (US$ 000’), Janouary’2020
Figure 22-4: Kymriah – Cost of Acute Lymphoblastic Leukemia Treatment (US$ 000’), Janouary’2020
Figure 22-5: Kymriah - Sales Value (US$ Million), 2017 & 2018
Figure 22-6: Kymriah – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 22-7: Yescarta - FDA Approval & US Patent Expiration Year
Figure 22-8: Yescarta - Cost of Advanced Lymphoma Treatment (US$ 000’), Janouary’2020
Figure 22-9: Yescarta - Sales Value (US$ Million), 2017 & 2018
Figure 22-10: Yescarta – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 28-1: Advaxis Clinical Pipeline
Figure 28-2: Celldex Therapeutics Clinical Pipeline
Figure 28-3: Expression Genetics Clinical Pipeline
Figure 28-4: Galena Biopharma Clinical Pipeline
Figure 28-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 28-6: ImmunoGen Clinical Pipeline
Figure 28-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 28-8: NewLink Genetics Corporation Clinical Pipeline
Figure 28-9: Northwest Biotherapeutics Clinical Pipeline
Figure 28-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 28-11: Philogen Clinical Pipeline
Figure 28-12: Seattle Genetics Clinical Pipeline
LIST OF TABLES
Table 5-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 7-1: Illustration of Some Important Checkpoint Inhibitors
Table 10-1: Few Important Immunocytokines under Clinical Development
Table 10-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 14-1: Few Commercially Important PD-1 Drugs
Table 5-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 7-1: Illustration of Some Important Checkpoint Inhibitors
Table 10-1: Few Important Immunocytokines under Clinical Development
Table 10-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 14-1: Few Commercially Important PD-1 Drugs
